Keely Macmillan, MSPH
Advertisement
Articles by Keely Macmillan, MSPH
COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
Advertisement
Latest Updated Articles
Biosimilars Drive Savings in Medicare’s Oncology Care ModelPublished: June 19th 2021 | Updated:
Three Ways COVID-19 Makes the Oncology Care First Model More AttractivePublished: October 29th 2020 | Updated:
- Rethinking Downside Risk Protection Amid Growth in Precision Medicine
Published: August 16th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
4
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
5
